Past performance does not predict future results. Informational only, not investment advice.
Surgical robots fill the gap created by fewer surgeons relative to rising surgical demand from aging populations. Expensive but potentially higher margin with less labour supply.
Leader in robotic surgical systems with significant market opportunity ahead. Preferred over Boston Scientific due to stronger growth trajectory and technology differentiation.
Intuitive Surgical has traded down ~40% from recent highs, creating a value opportunity in a consolidating surgical robotics market. Despite increasing competition, the company is likely to retain majority market share and trade valuations at levels historically considered expensive are now reasonable.
ISRG is trading at a compressed 35x forward multiple after falling one-third from January highs, despite still-strong high-teens procedure growth, 86% recurring revenue, and an enduring moat from surgeon training and installed base. The market appears to have priced in competitive losses from Hugo and Ottava that have not materialized in the actual numbers, creating a potential value entry.
Intuitive Surgical has a powerful EPS engine driven by a massive installed base, razor-and-blade recurring instrument revenue model, high switching costs, and very high margins with a long international runway.
Intuitive Surgical's stock decline is a buying opportunity despite slowing procedure growth guidance; the company grew earnings 24% and has 20%+ upside potential. Lower-cost product launches will defend its surgical-robot monopoly against new competition.
End of results.